Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 5/20 | 0.32 |
| ▸ | DRD4 | P21917 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5054147 | 0.76 | KMT2A (0.54) | MAPTPOLBTP53HTTLMNA | |
| SCHEMBL5054318 | 0.63 | MEN1 (0.62) | MAPTPOLBTP53HTTMEN1 | |
| SCHEMBL5057347 | 0.63 | MEN1 (0.61) | MAPTPOLBTP53HTTMEN1 | |
| SCHEMBL13807836 | 0.61 | NPC1 (0.56) | MAPTPOLBTP53HTTLMNA | |
| SCHEMBL5058757 | 0.60 | HTT (0.56) | MAPTPOLBTP53HTTLMNA | |
| SCHEMBL5058692 | 0.59 | CNR1 (0.66) | MAPTPOLBTP53HTTLMNA | |
| SCHEMBL21447968 | 0.57 | MAPT (0.53) | MAPTPOLBHTTLMNATSHR | |
| SCHEMBL10818397 | 0.56 | IGF1R (0.54) | MAPTPOLBHTTLMNATSHR | |
| SCHEMBL17749073 | 0.55 | SRC (0.45) | MAPTHTTLMNAALDH1A1HPGD | |
| SCHEMBL14542213 | 0.55 | TP53 (0.58) | MAPTPOLBTP53HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105819-A1 | CB-1 modulating compounds and their use | CNR1, CNR2, FAAH | MAPT 3344/4885POLB 4785/4885TP53 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.